Urine test could guide diabetes meds to protect heart and kidneys

NCT ID NCT06954090

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Steno Diabetes Center Copenhagen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study explores whether a simple urine protein test can help doctors decide which type 2 diabetes patients need extra medications to protect their heart and kidneys. Fifty adults with type 2 diabetes will receive semaglutide (Ozempic) and finerenone, and researchers will check if urine test results are available within two weeks. The goal is to see if this personalized approach is practical in everyday clinics.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (Ozempic) and Finerenone
What this could lead to: If successful, this could show that urine protein tests help doctors pick the right medications to prevent heart and kidney problems in people with type 2 diabetes.
What could go wrong: This is a small, early feasibility study with only 50 participants, so results may not apply to everyone. The main goal is to see if the testing process works, not to prove the treatments are effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALBUMINURIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Albuminuria diabetic kidney disease proteinuria type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALBUMINURIA TYPE 2 DM TYPE 2 DM /DIABETIC NEPHROPATHY

Contacts and locations

Locations

Steno Diabetes Center Copenhagen

Herlev, Hajdú-Bihar, 2730, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.